159 related articles for article (PubMed ID: 24089159)
1. Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term.
del Pozo-Fernández C; López-Menchero-Martínez R; Álvarez-Avellán L; Albero-Molina MD; Sánchez-Rodríguez L
Nefrologia; 2013; 33(5):675-84. PubMed ID: 24089159
[TBL] [Abstract][Full Text] [Related]
2. Kidney Disease Improving Global Outcomes guidelines and parathyroidectomy for renal hyperparathyroidism.
Oltmann SC; Madkhali TM; Sippel RS; Chen H; Schneider DF
J Surg Res; 2015 Nov; 199(1):115-20. PubMed ID: 25982045
[TBL] [Abstract][Full Text] [Related]
3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
4. Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.
Yokoyama K; Kurita N; Fukuma S; Akizawa T; Fukagawa M; Onishi Y; Kurokawa K; Fukuhara S
Nephrol Dial Transplant; 2017 Mar; 32(3):534-541. PubMed ID: 26945054
[TBL] [Abstract][Full Text] [Related]
5. Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.
Kovacevic B; Ignjatovic M; Zivaljevic V; Cuk V; Scepanovic M; Petrovic Z; Paunovic I
Langenbecks Arch Surg; 2012 Mar; 397(3):413-20. PubMed ID: 22240976
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience.
Tsai WC; Peng YS; Yang JY; Hsu SP; Wu HY; Pai MF; Chang JF; Chen HY
Blood Purif; 2013; 36(2):116-21. PubMed ID: 24217122
[TBL] [Abstract][Full Text] [Related]
7. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Tahara H
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
[TBL] [Abstract][Full Text] [Related]
9. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
Komaba H; Fukagawa M;
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
11. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
Yokoyama K
Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214
[No Abstract] [Full Text] [Related]
14. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism.
Zhang Y; Lu Y; Feng S; Zhan Z; Shen H
Ren Fail; 2019 Nov; 41(1):921-929. PubMed ID: 31573378
[No Abstract] [Full Text] [Related]
16. Achievement of the Japanese Society for Dialysis Therapy guideline targets for mineral metabolism measures: one Japanese university center result.
Kimata N; Miwa N; Otsubo S; Iwasaki T; Yabuki Y; Miyabe K; Asamiya Y; Sato K; Sugi O; Ikebe N; Kiuchi K; Mineshima M; Akiba T
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S62-6. PubMed ID: 17976088
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
18. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
19. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
20. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
